BMS Sues Mylan For $15M Over Improper HIV Drug Sales

Law360, New York (August 1, 2012, 5:04 PM EDT) -- Bristol-Myers Squibb Co. sued Mylan Inc. in New York on Monday for allegedly selling a generic version of HIV drug Reyataz in Venezuela, violating an agreement to sell the treatment in certain underdeveloped countries and costing BMS at least $15 million.

BMS claims that Mylan sold a year's supply of Reyataz, which goes by the generic name atazanvair, to an international health agency with the express purpose of distributing it in Venezuela, after BMS refused Mylan's request to sell the drug in the South American nation....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.